Infectious Diseases Associated with Organized Sports and Outbreak Control

Total Page:16

File Type:pdf, Size:1020Kb

Infectious Diseases Associated with Organized Sports and Outbreak Control CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care Infectious Diseases Associated H. Dele Davies, MD, MS, MHCM, FAAP, a Mary Anne Jackson, MD, FAAP,b Stephen G. Rice, MD, PhD, MPH, FAAP,c WithCOMMITTEE ON INFECTIOUS Organized DISEASES, COUNCIL ON SPORTSSports MEDICINE AND FITNESSand Outbreak Control Participation in organized sports has a variety of health benefits but also has abstract the potential to expose the athlete to a variety of infectious diseases, some of which may produce outbreaks. Major risk factors for infection include skin- to-skin contact with athletes who have active skin infections, environmental exposures and physical trauma, and sharing of equipment and contact aPediatric Infectious Diseases and Public Health, University of with contaminated fomites. Close contact that is intrinsic to team sports Nebraska Medical Center, Omaha, Nebraska; bInfectious Diseases, Children’s Mercy Kansas City and Department of Pediatrics, School and psychosocial factors associated with adolescence are additional risks. of Medicine, University of Missouri-Kansas City, Kansas City, Missouri; Minimizing risk requires leadership by the organized sports community and cSports Medicine, Jersey Shore University Medical Center and Department of Pediatrics, Robert Wood Johnson Medical School, (including the athlete’s primary care provider) and depends on outlining key Rutgers University, Neptune, New Jersey hygiene behaviors, recognition, diagnosis, and treatment of common sports- Dr Davies was the lead author of the manuscript; Drs Jackson and related infections, and the implementation of preventive interventions. Rice were coauthors of the manuscript with substantial input into content and revision; and all authors approved the final manuscript as submitted. This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy INTRODUCTION of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication. The definition of organized sports includes traditional team sports Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external commonly acknowledged as well as other types of sports (‍Table 1). reviewers. However, clinical reports from the American Academy of Participation in organized sports provides the benefits of (‍1) physical Pediatrics may not reflect the views of the liaisons or the organizations activity, by engaging in vigorous exercise, achieving fitness, and or government agencies that they represent. learning athletic skills; (‍2) socialization, by experiencing camaraderie The guidance in this statement does not indicate an exclusive course and learning teamwork and sportsmanship; and (‍3) competition, of treatment or serve as a standard of medical care. Variations, taking ’ into account individual circumstances, may be appropriate. by challenging oneself to perform against others, by striving to All clinical reports from the American Academy of Pediatrics continually improve oneself toward achieving one s full athletic 1 automatically expire 5 years after publication unless reaffirmed, potential, and by learning to win and lose with grace and dignity. revised, or retired at or before that time. Organized sports participation, however, can result in the acquisition of a variety of infectious diseases and conditions. Physical contact To cite: Davies HD, Jackson MA, Rice SG, AAP COMMITTEE among athletes, sharing of equipment (‍such as worn personal ON INFECTIOUS DISEASES, AAP COUNCIL ON SPORTS protective equipment or braces plus towels, drinking vessels, MEDICINE AND FITNESS. Infectious Diseases Associated showers, and locker rooms), and contact with– athletic surfaces (‍mats, With Organized Sports and Outbreak Control. Pediatrics. 2017;140(4):e20172477 artificial turf, dirt, grass, and gym or weight 2room9 equipment) can all be responsible for transmission of infection. In addition, certain organized sports carry specific additional risks; for example, wrestlers Downloaded from www.aappublications.org/news by guest on October 1, 2021 PEDIATRICS Volume 140, number 4, October 2017:e20172477 FROM THE AMERICAN ACADEMY OF PEDIATRICS Davies et al https://doi.org/10.1542/peds.2017-2477 October 2017 Infectious Diseases Associated With Organized Sports and Outbreak Control 4 140 Pediatrics 2017 ROUGH GALLEY PROOF Pediculosis capitis Pediculosis corporis Pediculosis pubis practicing in close quarters are and safety. Furthermore, because , especially 10,vulnerable 11 to skin pediatricians need to provide , and Escherichia), by infections. medical clearance to athletes to colicontaminatedShigella food orGiardia water (‍eg, participate in organized sports, Shiga-toxinCryptosporidium producing Athletes should be taught proper the preparticipation physical , species, personal hygiene (‍eg, hand-washing, examination is an opportunity to species, species, showering, and proper laundering– verify that the athlete does not and norovirus, which is further of uniforms and practice clothing 12 15 have a skin condition or infection propagated by the person-to-personNeisseria on a daily or regular basis). that could be transmitted to others. meningitidisroute), by respiratory droplet Avoidance of sharing of drinking This visit between the physician (‍eg, influenza, pertussis, vessels (‍water bottles, ladles, and the student athlete allows the , group A streptococcal or cups), mouth guards, towels, primary care pediatrician to deliver pharyngitis, mumps), by airborne braces, batting helmets, personal anticipatory guidance. Ensuring particles (‍eg, varicella, measles), or protective equipment, bars of soap, that immunizations are current per by certain vectors (‍eg, ticks) (‍Table 2). bath sponges, razors or electric recommendations of the Centers In the case of Epstein-Barr virus hair shavers, and– callus trimmers for Disease Control and Prevention, infection, close contact is required is also important2 9 in reducing the Advisory Committee on for transmission, and endemic infectious risk. In addition, Immunization Practices, and the disease within adolescent group athletic programs should ensure American Academy of Pediatrics is settings has been reported (‍Table 2). regular (‍daily, weekly, and monthly) important, and pediatric providers Although biologically plausible, cleaning of facilities and equipment should identify and document cases there have been no validated reports (‍eg, weight room,– railings, mats, in which vaccines are refused or of infections from transmission of blocking dummies,16 19 locker rooms, incomplete because of medical bloodborne pathogens, including and showers). Those who exemptions (‍eg, serious allergy to hepatitis B, hepatitis C, or HIV manage sports programs and a vaccine component). Coaches and during athletic competitions. facilities should develop a plan for trainers are primarily responsible Nonetheless, the American Academy proper cleaning and maintenance for reviewing and stressing to the of Pediatrics has previously issued of a sanitary sporting environment athlete the key hygiene behaviors specific detailed guidelines for by using guidelines such as those needed to minimize the risk of management of infections spread published by the American20 College obtaining or spreading infection by blood and body fluids, including of Sports Medicine. in organized sports. However, guidance for athletes who are primary care pediatricians can infected with HIV, hepatitis B virus, Special attention should be paid help reinforce such educational or hepatitis C virus, and these will to proper management of blood 21 21 messages. not be reiterated in this statement. and other body fluids. Just as ORGANISMS ASSOCIATED WITH hospitals in the United States have INFECTIONS IN ATHLETES Transmission of a specific infectious concentrated on preventing hospital- agent may be affected by a variety of associated infections in recent years, psychosocial (‍sexually transmitted the same level of focus on infection An athlete can acquire many infection), physical (‍trauma, prevention and control needs to different infections by participating closed community contact), and be present within the organized in organized sports. The pathogens environmental (‍soil, food, water, sports community, including ï include many that are prominent in vector) factors, especially in an among athletes, parents, coaches, outbreaks typically seen in crowded immunologically na ve population. athletic directors, equipment communities or closed community This policy will be focused on managers, certified athletic trainers, settings or that are facilitated by diagnosis, treatment, and prevention administrators, janitorial staff, team certain exposures specific to the of the most common infections that physicians, facility managers, and sport. may be encountered in the athlete league officials. participating in organized sports, Although the primary care StaphylococcusInfectious pathogens aureus include with an additional focus on factors pediatrician may appear to be those spread by skin contact (‍eg, that are potentially modifiable. peripheral in this athletic milieu Bacillus cereus , group It should be noted that some of of organized sports, leadership
Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • BRAND NAME COMPOSITION Packing Unit BRAND NAME
    BRAND NAME COMPOSITION Packing Unit DOIN-20 SOFT GEL CAP ISOTRETINOIN 20 MG SOFT GEL CAPS 10X1X10 BLISTER FENOGRAS 120 TAB FEXOFENADINE 120MG TABS 10X10 ALU ITRACHEM 100 CAP ITRACONAZOLE 100 MG CAPSULES 10X1X4 STRIP ITRACHEM 200 CAP ITRACONAZOLE 200 MG CAPSULES 10X1X4 STRIP KESHGAIN TABS BIOTIN10MG TABLETS(HAIR GROWTH TABS) 10X1X10 ALU SFLAZA 6 TAB DEFLAZACORT 6MG TABS 10X10 ALU TERBICHEM 250 TAB TERBINAFINE 250MG TABLETS 10X1X7 BLISTER AZYNEX 500 TAB AZITHROMYCIN 500 TAB 10X3 BLISTER BRAND NAME COMPOSITION Packing Unit BEAUTY SOAP WITH ALOE- ALOGLOW SOAP VERA,NEEM,KESAR,SANDAL,TULSI,OLIVE 75GM CARTOON OIL&GLYCERINE KETOLE SOAP KETOCONAZOLE 2% + CERTRIMIDE 0.5% 75GM CARTOON SCABICHEM SOAP PERMETHRIN 5% W/W 75GM CARTOON TRICLOSAN 0.2% + TEA TREE OIL + VIT E 0.4% + ULTRA-SHINE SOAP 75GM CARTOON TITANIUM DIOXIDE SHINE N BEAUTY SOAP NATURAL VIT.E WITH ALOE VERA SOAP 75GM CARTOON BRAND NAME COMPOSITION Packing Unit CALAMINE 15% W/V + ZINC OXIDE 5% W/V + CALACHEM LOTION 100ML CARTOON GLYCERINE 5% W/V CLEANSING LOTION (CETYL ALCOHOL 2.650% CETOCHEM LOTION 100ML CARTOON W/V + STEARYL ALCOHOL 0.260%W/V) CLOBSOL-S LOTION CLOBETASOL + SALICYLIC ACID 3% 50ML CARTOON KETOCONAZOLE 2%W/V + ZINC PYRITHIONE KETOLE-ZPTO SHAMPOO 50ML CARTOON 1%W/W SHAMPOO OCTYL METHOXY CINNAMATE 8% + SWISSGLOW-UV LOTION OXYBENZONE 6.5% + TITANIUM DIOXIDE 0.5% 100ML CARTOON SUNSCREEN LOTION SCABICHEM LOTION PERMETHRIN 5%W/V LOTION 50ML CARTOON BRAND NAME COMPOSITION Packing Unit CLINTOL POWDER CLOTRIMAZOLE 1%W/W POWDER 100GM SHRINK FINNOLE POWDER FLUCONAZOLE 0.5%W/W POWDER
    [Show full text]
  • Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies
    molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation.
    [Show full text]
  • Producing In-Situ Nanoparticles of Griseofulvin Using Supercritical Antisolvent Methodology
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 2013 Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology Pratik Sheth University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Sheth, Pratik, "Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology" (2013). Open Access Dissertations. Paper 25. https://digitalcommons.uri.edu/oa_diss/25 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. PRODUCING IN-SITU NANOPARTICLES OF GRISEOFULVIN USING SUPERCRITICAL ANTISOLVENT METHODOLOGY BY PRATIK SHETH A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2013 DOCTOR OF PHILOSOPHY DISSERTATION OF PRATIK SHETH APPROVED: Dissertation Committee: Major Professor M. Serpil Kislalioglu Ph.D David Worthen Ph.D. Michael L. Greenfield Ph.D Nasser H. Zawia Ph.D DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2013 ABSTRACT Poor aqueous solubility of drug candidates is a major challenge for the pharmaceutical scientists involved in drug development. Particle size reduction to nano scale appears as an effective and versatile option for
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • UTROGESTAN 100Mg Capsules Progesterone
    NEW ZEALAND DATA SHEET UTROGESTAN 100mg capsules Progesterone 1 PRODUCT NAME UTROGESTAN 100MG CAPSULES 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Soft, round, slightly yellow capsule containing a whitish oily suspension of 100 mg progesterone (micronised). Excipient(s) with known effect: Soya lecithin For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsules, soft 4 CLINICAL PARTICULARS 4.1 Therapeutic indications UTROGESTAN 100 mg capsule is indicated in adults, via the oral route, for: Hormone replacement therapy • Adjunctive use with an oestrogen in postmenopausal women with an intact uterus (for hormone replacement therapy [HRT]) 4.2 Dose and method of administration Dosage The recommended dose is as follows, according to the indication: Oral Route • In the treatment of menopause: oestrogen alone therapy is not recommended on its own in menopausal women with an intact uterus. The usual dose is 200 mg/day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapyfollowed by approximately one week without any replacement therapy and during which withdrawal bleeding may occur. Alternatively 100 mg can be given at bedtime, from days 1 to 25 of each cycle, withdrawal bleeding being less with this treatment schedule. Method of Administration This product is intended only for oral use. UTROGESTAN 100 mg should not be taken with food; it is preferable to take the capsules in the evening at bedtime. UTROGESTAN 100mg caps UTROGEST005 Jan 2018 Page 1 of 9 NEW ZEALAND DATA SHEET Oral Route Each capsule of UTROGESTAN 100 mg must be swallowed with a little water.
    [Show full text]
  • A Comparative Evaluation of Terbinafine and Eberconazole in the Management of Tinea Versicolor
    International Journal of Dermatology, Venereology and Leprosy Sciences. 2019; 2(2): 13-15 E-ISSN: 2664-942X P-ISSN: 2664-9411 www.dermatologypaper.com/ A comparative evaluation of Terbinafine and Derma 2019; 2(2): 13-15 Received: 13-05-2019 Eberconazole in the management of Tinea versicolor Accepted: 15-06-2019 Dr. Kalyani Mishra Dr. Kalyani Mishra Department of Dermatology, IPGMER and SSKM Hospital, DOI: https://doi.org/10.33545/26649411.2019.v2.i2a.26 Kolkata, West Bengal, India Abstract Introduction: Tinea versicolor is one of the most common infectious skin diseases that is seen in abundance during summer. The present study compared Terbinafine and Eberconazole in the management of Tinea versicolor. Materials & Methods: The present study was conducted on 235 cases (Group I) of Tinea versicolor of both genders. Patients were randomly divided into two study groups, i.e. Group I patients were given eberconazole 1% cream once daily for 2 weeks and Group II were given terbinafine 1% cream once daily for 2 weeks. Safety assessment was recorded. Results: Out of 240 patients, males were 125 and females were 115. In group I, 96 patients had complete healing while 72 patients in group II had complete healing, 24 in group I and 43 in group II had mild residual disease, 5 in group II had considerable residual. The difference was significant (P< 0.05). Conclusion: Authors found that eberconazole 1% cream was as effective as compared to terbinafine 1% in patients with Pityriasis versicolor. Keywords: Eberconazole, Terbinafine, Pityriasis versicolor Introduction Tinea versicolor (TV) or pityriasis versicolor, also known as Peter Elam’s disease, is one of [1] the most common infectious skin diseases that is seen in abundance during summer .
    [Show full text]
  • Review Article Sporotrichosis: an Overview and Therapeutic Options
    Hindawi Publishing Corporation Dermatology Research and Practice Volume 2014, Article ID 272376, 13 pages http://dx.doi.org/10.1155/2014/272376 Review Article Sporotrichosis: An Overview and Therapeutic Options Vikram K. Mahajan Department of Dermatology, Venereology & Leprosy, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India Correspondence should be addressed to Vikram K. Mahajan; [email protected] Received 30 July 2014; Accepted 12 December 2014; Published 29 December 2014 Academic Editor: Craig G. Burkhart Copyright © 2014 Vikram K. Mahajan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sporotrichosis is a chronic granulomatous mycotic infection caused by Sporothrix schenckii, a common saprophyte of soil, decaying wood, hay, and sphagnum moss, that is endemic in tropical/subtropical areas. The recent phylogenetic studies have delineated the geographic distribution of multiple distinct Sporothrix species causing sporotrichosis. It characteristically involves the skin and subcutaneous tissue following traumatic inoculation of the pathogen. After a variable incubation period, progressively enlarging papulo-nodule at the inoculation site develops that may ulcerate (fixed cutaneous sporotrichosis) or multiple nodules appear proximally along lymphatics (lymphocutaneous sporotrichosis). Osteoarticular sporotrichosis or primary pulmonary sporotrichosis are rare and occur from direct inoculation or inhalation of conidia, respectively. Disseminated cutaneous sporotrichosis or involvement of multiple visceral organs, particularly the central nervous system, occurs most commonly in persons with immunosuppression. Saturated solution of potassium iodide remains a first line treatment choice for uncomplicated cutaneous sporotrichosis in resource poor countries but itraconazole is currently used/recommended for the treatment of all forms of sporotrichosis.
    [Show full text]
  • Divestra Leaflet
    • Known or suspected estrogen-dependent neoplasia Drugs which may decrease the therapeutic effect of Cyproterone acetate+Ethinyl Pregnancy and Breastfeeding • Undiagnosed abnormal vaginal bleeding Combination of Cyproterone acetate and Ethinyl estradiol is contraindicated during estradiol and increase the incidence of breakthrough bleeding • Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete pregnancy and breastfeeding. loss of vision or defect in visual fields Effects on ability to drive and use machines • Concomitant use with other Estrogen+Progestogen combinations or estrogens or Unknown progestogens alone • When pregnancy is suspected or diagnosed Adverse Reactions • Severe diabetes with vascular changes Common adverse reactions includes headaches, nausea, abdominal pain, weight gain, • A history of otosclerosis with deterioration during pregnancy depressed or altered mood and breast pain or tenderness. • Hypersensitivity to this drug or to any ingredient in the formulation or component of the Uncommon adverse reactions include vomiting, diarrhea, fluid retention and migraine. container. Overdose (Cyproterone acetate + Warnings and Precautions There is no antidote and treatment should be symptomatic. Ethinyl estradiol) Discontinue Cyproterone acetate+Ethinyl estradiol tablets at the earliest manifestation of the following: PHARMACOLOGICAL PROPERTIES • Thromboembolic and Cardiovascular Disorders such as thrombophlebitis, pulmonary Pharmacotherapeutic group: Sex hormones and modulators of the genital system, QUALITATIVE AND QUANTITATIVE COMPOSITION embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and anti-androgens and estrogens. ATC code: G03HB01 Each film-coated tablet contains: retinal thrombosis. Cyproterone acetate (Ph.Eur.)………...2 mg • Conditions that predispose to Venous Stasis and to Vascular Thrombosis (eg. Mechanism of action Ethinyl estradiol (USP)……………...0.035 mg immobilization after accidents or confinement to bed during long-term illness).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Antifungals, Topical
    Antifungals, Topical Therapeutic Class Review (TCR) November 17, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. November
    [Show full text]